“…The most recent researches on new compounds or drugs with schistosomicidal activity have been carried out with: a) inhibitors of cysteine protease, such as K11777, considered a powerful schistosomicide that reduces the pathogenesis of experimental schistosomiasis (Abdulla et al, 2007), b) RNAi, in the attempt to develop drugs or compounds that act as enzyme silencers, e.g., the compound 4-phenyl-1,2,5-oxadiazole-3-carbonitrile-2-oxide, or furoxan, which acts on thioredoxin-glutathione reductase from S. mansoni (Kuntz et al, 2007, Sayed et al, 2008, c) trioxolanes or secondary ozonides (1, 2, 4-trioxolanes), which comprehend a class of synthetic endoperoxides that are cheap, easily synthesised, and similar to artemisinins, having activity on experimental infections with S. mansoni and S. japonicum (Caffrey, 2007, Xiao et al, 2007, d) mefloquine (antimalarial), which showed schistosomicidal activity against young and adult S. mansoni worms (Van Nassauw et al, 2008, Keiser et al, 2009), e) arachidonic acid, which showed schistosomicidal properties against S. mansoni and S. haematobium ( E l R i d i e t a l . , 2010), and f) miltefosine (antileishmania), which reduced the parasite burden of mice infected with S. mansoni (Eissa et al, 2011). At the present moment there are no clinical assays with these compounds.…”